Novel chenodeoxycholic acid–sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study

Abstract Context: We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes. Objective: The objective of this study is to optimize this platform by incorporating Chenodeoxycholic acid (CDCA), a bile acid with good permeation-enhancing properties, and examine its effect in vitro. Using sodium alginate (SA), we prepared PB-SA (control) and PB-CDCA-SA (test) microcapsules. Results and discussion: CDCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained unchanged. PB-CDCA-SA microcapsules showed good excipients’ compatibilities, as evidenced by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy, scanning electron microscopy and energy dispersive X-ray spectroscopy studies. CDCA reduced microcapsule swelling at pH 7.8 at both 37 °C and 25 °C and improved PB-release. Conclusion: CDCA improved the characteristics and release properties of PB-microcapsules and may have potential in the targeted oral delivery of PB.

[1]  F. Arfuso,et al.  Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells , 2016, Artificial cells, nanomedicine, and biotechnology.

[2]  H. Al‐Salami,et al.  An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations , 2015, Pharmaceutical development and technology.

[3]  Hesham S. Al-Sallami,et al.  Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes , 2015, AAPS PharmSciTech.

[4]  G. Watts,et al.  An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer , 2014, Drug design, development and therapy.

[5]  Hesham S. Al-Sallami,et al.  Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol , 2014, Drug design, development and therapy.

[6]  Hesham S. Al-Sallami,et al.  Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study , 2014, Drug design, development and therapy.

[7]  H. Al‐Salami,et al.  Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics , 2014, Journal of Pharmaceutical Innovation.

[8]  G. Kulkarni,et al.  Development of novel gastroretentive drug delivery system of gliclazide: hollow beads , 2014, Drug development and industrial pharmacy.

[9]  H. Al‐Salami,et al.  Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System , 2013 .

[10]  G. Kulkarni,et al.  Development of novel gastroretentive floating particulate drug delivery system of gliclazide. , 2012, Current drug delivery.

[11]  R. Yumoto,et al.  Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption , 2012, Drug development and industrial pharmacy.

[12]  S. Takka,et al.  Bile salt-reinforced alginate-chitosan beads , 2012, Pharmaceutical development and technology.

[13]  Christopher A. Bonino,et al.  "Real-time in-situ Rheology of Alginate Hydrogel Photocrosslinking." , 2011 .

[14]  Micheal Whelehan,et al.  Microencapsulation using vibrating technology , 2011, Journal of microencapsulation.

[15]  K. Draget,et al.  Chemical, physical and biological properties of alginates and their biomedical implications , 2011 .

[16]  B. Ranjbar,et al.  Differential scanning calorimetry techniques: applications in biology and nanoscience. , 2010, Journal of biomolecular techniques : JBT.

[17]  L. Marciani,et al.  NMR relaxometry and rheology of ionic and acid alginate gels. , 2010 .

[18]  J. G. Torre,et al.  The influence of mono and divalent cations on dilute and non-dilute aqueous solutions of sodium alginates , 2010 .

[19]  Richard Barnett.  Historical keyword: diabetes. , 2010, Lancet.

[20]  S. Yamashita,et al.  Where are we with probucol: a new life for an old drug? , 2009, Atherosclerosis.

[21]  Sun Yan,et al.  Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study , 2009 .

[22]  R. Stocker,et al.  Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds , 2008, Redox report : communications in free radical research.

[23]  C. Chittleborough,et al.  The increasing prevalence of diabetes in South Australia: the relationship with population ageing and obesity. , 2007, Public health.

[24]  T. E. Abraham,et al.  Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan--a review. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[25]  M. Mikov,et al.  Structure and origin of bile acids: An overview , 2006, European Journal of Drug Metabolism and Pharmacokinetics.

[26]  J. Manson,et al.  Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes , 2004, Diabetologia.

[27]  K. Schmid,et al.  Knowledge of the ocular effects of diabetes among the general population of Australia and the members of Diabetes Australia , 2003, Clinical & experimental optometry.

[28]  H. Kaneto,et al.  Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. , 2002, Diabetes research and clinical practice.

[29]  A. R. Kulkarni,et al.  In-vitro release kinetics of cefadroxil-loaded sodium alginate interpenetrating network beads. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  Kunio Ito,et al.  A Nifedipine Coground Mixture with Sodium Deoxycholate. I. Colloidal Particle Formation and Solid-State Analysis , 2001, Drug development and industrial pharmacy.

[31]  Jack Legrand,et al.  Diffusion coefficients of ferricyanide ions in polymeric solutions — comparison of different experimental methods , 2000 .

[32]  K. Yamamoto,et al.  Effects of dietary fat levels on the absorption and tissue accumulation of probucol in the rat. , 1994, Arzneimittel-Forschung.

[33]  R. N. Brogden,et al.  Probucol , 1989, Drugs.

[34]  J. Goto,et al.  [Isolation and determination of bile acids]. , 1984, Nihon rinsho. Japanese journal of clinical medicine.

[35]  R. N. Brogden,et al.  Probucol: A Review of its Pharmacological Properties and Therapeutic Use in Patients with Hypercholesterolaemia , 1978, Drugs.

[36]  O. Campanella,et al.  Rheological investigation of alginate chain interactions induced by concentrating calcium cations , 2013 .

[37]  D. Blankenhorn,et al.  Principles and Treatment of Lipoprotein Disorders , 1994, Handbook of Experimental Pharmacology.

[38]  H. Shimizu,et al.  Probucol attenuated hyperglycemia in multiple low-dose streptozotocin-induced diabetic mice. , 1991, Life sciences.

[39]  Antonio Gaddi,et al.  Atherosclerosis and Cardiovascular Disease , 1990, Springer Netherlands.